PT - JOURNAL ARTICLE AU - Jemma L Geoghegan AU - Jordan Douglas AU - Xiaoyun Ren AU - Matthew Storey AU - James Hadfield AU - Olin K Silander AU - Nikki E Freed AU - Lauren Jelley AU - Sarah Jefferies AU - Jillian Sherwood AU - Shevaun Paine AU - Sue Huang AU - Andrew Sporle AU - Michael G Baker AU - David R Murdoch AU - Alexei J Drummond AU - David Welch AU - Colin R Simpson AU - Nigel French AU - Edward C Holmes AU - Joep de Ligt TI - The power and limitations of genomics to track COVID-19 outbreaks: a case study from New Zealand AID - 10.1101/2020.10.28.20221853 DP - 2020 Jan 01 TA - medRxiv PG - 2020.10.28.20221853 4099 - http://medrxiv.org/content/early/2020/11/03/2020.10.28.20221853.short 4100 - http://medrxiv.org/content/early/2020/11/03/2020.10.28.20221853.full AB - Background Real-time genomic sequencing has played a major role in tracking the global spread and local transmission of SARS-CoV-2, contributing greatly to disease mitigation strategies. After effectively eliminating the virus, New Zealand experienced a second outbreak of SARS-CoV-2 in August 2020. During this August outbreak, New Zealand utilised genomic sequencing in a primary role to support its track and trace efforts for the first time, leading to a second successful elimination of the virus.Methods We generated the genomes of 80% of the laboratory-confirmed samples of SARS-CoV-2 from New Zealand’s August 2020 outbreak and compared these genomes to the available global genomic data.Findings Genomic sequencing was able to rapidly identify that the new COVID-19 cases in New Zealand belonged to a single cluster and hence resulted from a single introduction. However, successful identification of the origin of this outbreak was impeded by substantial biases and gaps in global sequencing data.Interpretation Access to a broader and more heterogenous sample of global genomic data would strengthen efforts to locate the source of any new outbreaks.Funding This work was funded by the Ministry of Health of New Zealand, New Zealand Ministry of Business, Innovation and Employment COVID-19 Innovation Acceleration Fund (CIAF-0470), ESR Strategic Innovation Fund and the New Zealand Health Research Council (20/1018 and 20/1041).Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by the Ministry of Health of New Zealand, New Zealand Ministry of Business, Innovation and Employment COVID-19 Innovation Acceleration Fund (CIAF-0470), ESR Strategic Innovation Fund and the New Zealand Health Research Council (20/1018 and 20/1041).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available on GISAID database https://www.gisaid.org/